Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?

By H. Onishi, H. Shirato, Y. Nagata, M. Hiraoka, Masaharu Fujino, K. Gomi, K. Karasawa, K. Hayakawa, Y. Niibe, Y. Takai and 10 more. International Journal of Radiation Oncology, Biology, Physics, 2011

608 citations recorded by the source corpus.

Subfields: Hepatology, Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/db3ef4ffa004e335266275fa5d32989621b97753

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Zappa
2. Shaker A. Mousa

Citations in the corpus

• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, unknown): “Despite the available data on outcomes of SABR in patients with peripheral stage I tumours who are fit to undergo surgery [91, 92], there is currently no evidence to routinely recommend SABR for patients who are at low risk for surgical complications.”
• Non-small cell lung cancer: current treatment and future advances. (2016, result): “As a result of these studies and some others, SBRT has been found to offer local control and outcomes approaching surgical resection with lower rates of treatment-related morbidity (46,47).”